Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 10/20 | 0.84 |
| ▸ | EGFR | P00533 | 17/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29886851 | 1.00 | BTK (0.84) | BTKEGFR | |
| SCHEMBL18665661 | 0.91 | BTK (1.00) | BTKEGFR | |
| SCHEMBL31071137 | 0.90 | EGFR (0.75) | BTKEGFR | |
| SCHEMBL18665653 | 0.88 | EGFR (1.00) | BTKEGFR | |
| SCHEMBL29617720 | 0.88 | EGFR (1.00) | BTKEGFR | |
| SCHEMBL31070351 | 0.88 | EGFR (0.72) | BTKEGFR | |
| SCHEMBL31071255 | 0.87 | EGFR (0.71) | BTKEGFR | |
| SCHEMBL31071219 | 0.86 | EGFR (0.72) | BTKEGFR | |
| SCHEMBL24735215 | 0.84 | EGFR (0.86) | BTKEGFR | |
| SCHEMBL18665608 | 0.84 | EGFR (1.00) | BTKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4116303-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | Loxo Oncology, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-4116303-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | Loxo Oncology, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-3350184-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | LOXO ONCOLOGY INC (US) | 2022-10-19 | — | — | EP | disclosed |
| US-10611766-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | LOXO ONCOLOGY INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-10611766-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | LOXO ONCOLOGY INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-10399989-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | LOXO ONCOLOGY, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399990-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | LOXO ONCOLOGY, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399989-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | LOXO ONCOLOGY, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399990-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | LOXO ONCOLOGY, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180362533-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | REDX PHARMA PLC. (GB) | 2018-12-20 | — | — | US | disclosed |
| US-20180362537-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | REDX PHARMA PLC (GB) | 2018-12-20 | — | — | US | disclosed |
| US-20180298008-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | REDX PHARMA PLC (GB) | 2018-10-18 | — | — | US | disclosed |
| WO-2017046604-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | REDX PHARMA PLC (GB) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611766-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | BTK, SYK, LCK | BTK 1/4885EGFR 740/4885 |
| US-10399990-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | BTK, SYK, LCK | BTK 1/4885EGFR 740/4885 |
| US-10399989-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | BTK, SYK, LCK | BTK 1/4885EGFR 740/4885 |
| US-20180362537-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | BTK, SYK, LCK | BTK 1/4885EGFR 740/4885 |
| US-20180298008-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | BTK, SYK, LCK | BTK 1/4885EGFR 740/4885 |
| US-20180362533-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | BTK, SYK, LCK | BTK 1/4885EGFR 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.